Statistics about Health, Pharma & Medtech in United States
Statistics
- Preferred methods of choice for sharing wearable health data in the U.S. 2023
- Yearly time savings using 3D-printed guides in surgery 2019, by specialty
- Yearly cost savings using 3D-printed guides in surgery 2019, by specialty
- Possible cost savings using 3D-printed guides in surgery 2019
- Possible time saved using 3D-printed guides in surgery 2019
- Types of chatbots used in medical practices in the U.S. in 2023
- Main medical chatbot applications for patients in the U.S. in 2023
- Reasons for sharing data from personal devices with doctors in the U.S. 2023
- Doctors' trust in chatbots' abilities in the U.S. in 2023
- Likelihood of choosing a doctor who uses wearable data in the U.S. 2023
- Use of various hearing aids by market share in U.S. 2021
- Value of medical device imports from the U.S. to Taiwan 2014-2019
- Annual change in U.S. hearing aid sales by sector 2007-2018
- Important factors for U.S. audiologists when selecting patient's hearing aids 2018
- US private hearing aid market by company 2016
- Adoption rate of hearing aids by HI people in select developed countries 2014-2015
- Sales market share of hearing aid companies U.S. 2015
- Number of retail outlets of hearing aid companies U.S. 2015
- FDA support for over the counter hearing aids by industry and consumers US 2015
- FDA support for over the counter hearing aids by surveyed group U.S. 2015
- Injuries from crutches, canes and walkers in the U.S 2002-2010
- Moderna total assets 2016-2025
- Moderna net income 2016-2025
- R&D expenses of Moderna 2016-2025
- Moderna Inc collaboration revenue by related party 2018-2025
- Number of biotech start-ups launched in the U.S. and the EU-27 2000-2022
- Amgen cash flow 2004-2025
- Amgen net income 2009-2025
- Amgen research and development expenditure 2006-2025
- Amgen revenue 2004-2025
- Revenue of AbbVie's Humira 2011-2025
- Amgen expenditure on research and development by category 2020-2025
- Eli Lilly and Company's top products based on revenue 2025
- Major pharma and biotech drug launches in 2026, by revenue estimates for 2032
- Expected top life science startups in the U.S. 2024-2025
- Patents filed in the U.S. vs. Japan for top selling U.S. drugs, as of August 2020
- Amount of top U.S. biotech venture financings 2024
- Value of top U.S. biotech IPOs 2024
- Disparities median price Lantus by select countries 2022
- Regeneron Pharmaceuticals top product net sales 2021-2024
- Antimicrobial drugs for U.S. livestock sales share by route of administration 2023
- U.S. bioscience venture capital investments 2009-2023
- U.S. average annual wages per employee by industry 2023
- U.S. bioscience establishments totals 2019-2023
- Share of filgrastim sales attributable to Neupogen or biosimilars US 2015-2024
- Number of trials investigating Perjeta by country 2024
- mRNA vaccine and therapy market value U.S. 2020-2030
- Physician office payment for biosimilars in Medicare Part B 2022
- Number of public biotech companies in the U.S. 2021 by region
- U.S. and Europe's selected anti-CD19 Car-T therapy sales forecast 2024
- Cumulative number of drugs with biosimilars approved US and Europe 2006-2018
- YTD stock performance of biopharma companies working on COVID March 2020
- Size of the total U.S. vaccine market 2014-2024
- Cell-free DNA based cancer diagnostic and screening market US vs. world 2020
- Loss of Lantus sales to U.S. biosimilars 2015-2017
- Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020
- IPO value of select CAR-T companies 2013-2015
- Venture capital funding for companies in CAR-T programs 2011-2016
- Legal cannabis industry investments on biotech in the U.S. 2015-2017
- Leading firms in venture capital funding in U.S. biotech companies 2015, by amount
- Leading firms in venture capital funding in U.S. biotech companies 2015, by deals
- Potential biosimilars savings in EU5 countries and the U.S. 2016-2020
- U.S. consumers knowledge about biosimilars 2015
- Talkspace total assets 2021-2025
- Lifestance Health Group liabilities 2021-2025
- Genedx Holdings Corp. liabilities 2021-2025
- Achari Ventures Holdings liabilities 2021-2023
- Sharecare, Inc. liabilities 2020-2023
- Better Therapeutics, Inc. liabilities 2020-2022
- Docgo Inc. total assets 2021-2025
- Vsee Health, Inc. total assets 2021-2025
- Innovage Holding total assets 2021-2025
- American Oncology Network, Inc. total assets 2020-2024
- Pear Therapeutics, Inc. total assets 2020-2022
- Lifestance Health Group total assets 2021-2025
- Privia Health Group liabilities 2021-2025
- Mitesco total assets 2021-2025
- Better Therapeutics, Inc. total assets 2020-2022
- American Oncology Network, Inc. liabilities 2020-2024
- Vsee Health, Inc. liabilities 2021-2025
- Mitesco liabilities 2021-2025
- Genedx Holdings Corp. total assets 2021-2025
- P3 Health Partners Inc. total assets 2021-2025
- Advanzeon Solutions total assets 2015-2019
- Privia Health Group total assets 2021-2025
- Advanzeon Solutions liabilities 2015-2019
- The Pennant Group total assets 2021-2025
- Innovage Holding liabilities 2021-2025
- Medicale total assets 2021-2025
- Achari Ventures Holdings total assets 2021-2023
- Sharecare, Inc. total assets 2020-2023
- P3 Health Partners Inc. liabilities 2021-2025
- Docgo Inc. liabilities 2021-2025
- Privia Health Group operating profit 2021-2025
- Docgo Inc. net income 2021-2025
- Docgo Inc. net cash 2021-2025
- Vsee Health, Inc. total equity 2021-2025
- Privia Health Group net income 2021-2025
- Mitesco operating profit 2021-2025
- Privia Health Group revenue 2021-2025